Treatment of Bowen's disease with photodynamic therapy. Observational study in 171 patients with 5-aminolaevulinic acid (BF-200 ALA) and methyl aminolaevulinate (MAL)

被引：10
|
作者：
Alique-Garcia, Sergio [1 ,2 ]
Alique, Daniel [3 ]
Company-Quiroga, Jaime [1 ]
Sanchez, Alberto [2 ,4 ]
Hernandez Nunez, Almudena [1 ]
Borbujo, J. [1 ]
机构：
[1] Hosp Univ Fuenlabrada, Dept Dermatol, C Camino Molino 2, Madrid 28942, Spain
[2] Univ Rey Juan Carlos, Madrid, Spain
[3] Univ Politecn Madrid, Sch Agr Food & Biosyst Engn, Madrid, Spain
[4] Res Ctr Computat Simulat, Madrid, Spain
来源：
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY | 2019年 / 28卷
关键词：
Bowen's disease; Photodynamic therapy; 5-aminolaevulinic acid; Methyl aminolaevulinate; SQUAMOUS-CELL CARCINOMA; SKIN;
D O I：
10.1016/j.pdpdt.2019.08.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
An observational study was carried out in the photodynamic therapy (PDT) section of Fuenlabrada's hospital (Madrid, Spain). Our goal was to investigate the efficacy and safety of PDT in Bowen's disease (BD). Between June 2011-June 2017 171 patients (191 lesions) with diagnosis of BD were enrolled in the study (95 women and 76 men; average age of 74.31 years). Lesions were treated with one 5-aminolaevulinic acid (BF-200 ALA)-PDT or methyl-5-aminolaevulinate (MAL)-PDT cycle of two sessions in one week. A second treatment cycle was performed in cases of clinical persistence at 12 weeks. Our results showed that 47/55 lesions were resolved (84.75%) after one or two ALA-PDT cycle and 75/136 lesions (55.15%) after one or two MAL-PDT cycles, in the 12-month follow-up. In conclusion PDT is a safe and non-invasive treatment option in BD. In addition, our results suggest a better response with ALA-PDT over MAL-PDT. Limits: observational study with a limited number of patients.
引用
收藏
页码：192 / 194
页数：3
相关论文
共 50 条
  • [11] Treatment of superficial basal cell carcinoma with 7.8% 5-aminolaevulinic acid nanoemulsion-based gel (BF-200 ALA) and photodynamic therapy: Results in clinical practice in a tertiary hospital
    Navarro-Trivino, Francisco Jose
    Ayen-Rodriguez, Angela
    Llamas-Molina, Jose Maria
    Saenz-Guirado, Soledad
    Ruiz-Villaverde, Ricardo
    DERMATOLOGIC THERAPY, 2021, 34 (01)
  • [12] Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo
    Dirschka, T.
    Radny, P.
    Dominicus, R.
    Mensing, H.
    Bruening, H.
    Jenne, L.
    Karl, L.
    Sebastian, M.
    Oster-Schmidt, C.
    Kloevekorn, W.
    Reinhold, U.
    Tanner, M.
    Groene, D.
    Deichmann, M.
    Simon, M.
    Huebinger, F.
    Hofbauer, G.
    Kraehn-Senftleben, G.
    Borrosch, F.
    Reich, K.
    Berking, C.
    Wolf, P.
    Lehmann, P.
    Moers-Carpi, M.
    Hoenigsmann, H.
    Wernicke-Panten, K.
    Helwig, C.
    Foguet, M.
    Schmitz, B.
    Luebbert, H.
    Szeimies, R. -M.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (01) : 137 - 146
  • [13] Photodynamic therapy (PDT) for Barrett's oesophagus: Establishing the optimum dose of 5-aminolaevulinic acid (ALA)
    Kelty, CJ
    Ackroyd, R
    Brown, NJ
    Brown, SB
    Stephenson, TJ
    Reed, MWR
    GUT, 2002, 50 : A123 - A123
  • [14] Photodynamic therapy using 5-aminolaevulinic acid for the treatment of dysplsia in Barrett's oesophagus
    Dunn, Jason
    Lovat, Laurence
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (05) : 851 - 858
  • [15] Timing of 5-aminolaevulinic acid-induced photodynamic therapy for the treatment of patients with Barrett's oesophagus
    Hinnen, P
    de Rooij, FWM
    Hop, WCJ
    Edixhoven, A
    van Dekken, H
    Wilson, JHP
    Siersema, PD
    JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY, 2002, 68 (01) : 8 - 14
  • [16] A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy
    Morton, C. A.
    Dominicus, R.
    Radny, P.
    Dirschka, T.
    Hauschild, A.
    Reinhold, U.
    Aschoff, R.
    Ulrich, M.
    Keohane, S.
    Ekanayake-Bohlig, S.
    Ibbotson, S.
    Ostendorf, R.
    Berking, C.
    Groene, D.
    Schulze, H. J.
    Ockenfels, H. M.
    Jasnoch, V.
    Kurzen, H.
    Sebastian, M.
    Stege, H.
    Staubach, P.
    Gupta, G.
    Huebinger, F.
    Ziabreva, I.
    Schmitz, B.
    Gertzmann, A.
    Luebbert, H.
    Szeimies, R. -M.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (02) : 309 - 319
  • [17] Photodynamic therapy with BF-200 ALA gel for the treatment of actinic keratosis, Bowen<acute accent>s disease and basal cell carcinoma in long term immunosuppressed patients after organ transplantation
    Gonzalez-Guerra, Elena
    Taboada, Alberto Conde
    Munoz, Lucia Campos
    Fructuoso, Ana Isabel Sanchez
    PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2024, 45
  • [18] Simulated-daylight photodynamic therapy with BF-200 aminolaevulinic acid for actinic keratosis: assessment of the efficacy and tolerability in a retrospective study
    Kellner, C.
    Bauriedl, S.
    Hollstein, S.
    Reinhold, U.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (04) : 1146 - 1148
  • [19] A randomized, double-blind trial comparing 5-aminolaevulinic acid nanoemulsion with methyl 5-aminolaevulinate in daylight photodynamic therapy for actinic keratosis
    Szeimies, R. M.
    Calzavara-Pinton, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (01) : 223 - 224
  • [20] A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the treatment of actinic keratosis
    Dirschka, T.
    Ekanayake-Bohlig, S.
    Dominicus, R.
    Aschoff, R.
    Herrera-Ceballos, E.
    Botella-Estrada, R.
    Hunfeld, A.
    Kremser, M.
    Schmitz, B.
    Luebbert, H.
    Puig, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (02) : 288 - 297
12345